Jillian Pintye1, Yanling Huo2, Deborah Kacanek2, Kevin Zhang3, Karen Kuncze3, Hideaki Okochi3, Monica Gandhi3. 1. Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, Washington. 2. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 3. Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Abstract
OBJECTIVE: We evaluated peripartum tenofovir (TFV) exposure via hair measures among women living with HIV in the United States. DESIGN: Observational cohort study. METHODS: Hair samples were collected at or shortly after childbirth among mothers enrolled in the Surveillance Monitoring for Antiretroviral Therapy Toxicities Study of the Pediatric HIV/AIDS Cohort Study between 6/2014 and 7/2016. Among mothers receiving TFV disoproxil fumarate (TDF)-based regimens during pregnancy, TFV hair concentrations were analyzed using liquid chromatography/tandem mass spectrometry. Weight-normalized TFV concentrations were log10 transformed. Multivariable linear regression assessed correlates of TFV concentrations. RESULTS: Overall, 121 mothers on TDF-based antiretroviral therapy during pregnancy had hair specimens tested for TFV concentrations and were included in the analysis. Median age at delivery was 31 years [interquartile range (IQR) 26-36]; 71% self-identified as non-Hispanic black, and 10% had unsuppressed viral loads in late pregnancy (HIV RNA ≥ 400 copies/ml). Median time from birth to hair collection was 3 days (IQR 1-14) and median TFV hair concentration was 0.02 ng/mg (IQR 0.01-0.04). In multivariable models, an unsuppressed viral load in late pregnancy was associated with 80% lower adjusted mean peripartum TFV concentrations than pregnancies with viral suppression (95% confidence interval: -90% to -59%, P < 0.001). Use of TDF only in the first trimester and attaining high school graduation were also associated with lower TFV hair concentrations. CONCLUSION: Unsuppressed viral load during late pregnancy was strongly associated with lower maternal TFV hair concentrations at birth, though viremia was rare. Efforts to improve maternal virological outcomes and eliminate vertical HIV transmission could incorporate drug exposure monitoring using hair or other metrics.
OBJECTIVE: We evaluated peripartum tenofovir (TFV) exposure via hair measures among women living with HIV in the United States. DESIGN: Observational cohort study. METHODS: Hair samples were collected at or shortly after childbirth among mothers enrolled in the Surveillance Monitoring for Antiretroviral Therapy Toxicities Study of the Pediatric HIV/AIDS Cohort Study between 6/2014 and 7/2016. Among mothers receiving TFV disoproxil fumarate (TDF)-based regimens during pregnancy, TFV hair concentrations were analyzed using liquid chromatography/tandem mass spectrometry. Weight-normalized TFV concentrations were log10 transformed. Multivariable linear regression assessed correlates of TFV concentrations. RESULTS: Overall, 121 mothers on TDF-based antiretroviral therapy during pregnancy had hair specimens tested for TFV concentrations and were included in the analysis. Median age at delivery was 31 years [interquartile range (IQR) 26-36]; 71% self-identified as non-Hispanic black, and 10% had unsuppressed viral loads in late pregnancy (HIV RNA ≥ 400 copies/ml). Median time from birth to hair collection was 3 days (IQR 1-14) and median TFV hair concentration was 0.02 ng/mg (IQR 0.01-0.04). In multivariable models, an unsuppressed viral load in late pregnancy was associated with 80% lower adjusted mean peripartum TFV concentrations than pregnancies with viral suppression (95% confidence interval: -90% to -59%, P < 0.001). Use of TDF only in the first trimester and attaining high school graduation were also associated with lower TFV hair concentrations. CONCLUSION: Unsuppressed viral load during late pregnancy was strongly associated with lower maternal TFV hair concentrations at birth, though viremia was rare. Efforts to improve maternal virological outcomes and eliminate vertical HIV transmission could incorporate drug exposure monitoring using hair or other metrics.
Authors: Katherine Tassiopoulos; Jennifer S Read; Susan Brogly; Kenneth Rich; Barry Lester; Stephen A Spector; Ram Yogev; George R Seage Journal: AIDS Behav Date: 2010-12
Authors: L Myer; T K Phillips; J A McIntyre; N-Y Hsiao; G Petro; A Zerbe; J Ramjith; L-G Bekker; E J Abrams Journal: HIV Med Date: 2016-06-28 Impact factor: 3.180
Authors: Monica Gandhi; Pamela M Murnane; Peter Bacchetti; Richard Elion; Michael A Kolber; Stephanie E Cohen; Howard Horng; Alexander Louie; Karen Kuncze; Catherine A Koss; Peter L Anderson; Susan Buchbinder; Albert Liu Journal: AIDS Date: 2017-10-23 Impact factor: 4.177
Authors: Jeffrey Sa Stringer; Moses Sinkala; Courtney C Maclean; Jens Levy; Chipepo Kankasa; Alain Degroot; Elizabeth M Stringer; Edward P Acosta; Robert L Goldenberg; Sten H Vermund Journal: AIDS Date: 2005-08-12 Impact factor: 4.177
Authors: Jean B Nachega; Michael Hislop; David W Dowdy; Richard E Chaisson; Leon Regensberg; Gary Maartens Journal: Ann Intern Med Date: 2007-04-17 Impact factor: 25.391
Authors: Elizabeth M Stringer; Didier K Ekouevi; David Coetzee; Pius M Tih; Tracy L Creek; Kathryn Stinson; Mark J Giganti; Thomas K Welty; Namwinga Chintu; Benjamin H Chi; Catherine M Wilfert; Nathan Shaffer; Francois Dabis; Jeffrey S A Stringer Journal: JAMA Date: 2010-07-21 Impact factor: 56.272
Authors: Maria Pyra; Peter L Anderson; Craig W Hendrix; Renee Heffron; Kenneth Mugwanya; Jessica E Haberer; Katherine K Thomas; Connie Celum; Deborah Donnell; Mark A Marzinke; Elizabeth A Bukusi; Nelly R Mugo; Stephen Asiimwe; Elly Katabira; Jared M Baeten Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: Catherine A Koss; Sybil G Hosek; Peter Bacchetti; Peter L Anderson; Albert Y Liu; Howard Horng; Leslie Z Benet; Karen Kuncze; Alexander Louie; Parya Saberi; Craig M Wilson; Monica Gandhi Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079